Neuren previously reported positive results in the Magel-2 mouse model of Prader-Willi syndrome, in which treatment with NNZ-2591 for 6 weeks normalized fat mass, insulin levels, IGF1 levels and all behavioural deficits.
And this is why I expect this particular trial to be keenly watched...
Ann: Prader-Willi syndrome IND for NNZ-2591 approved by FDA, page-5
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.86 |
Change
-0.110(0.55%) |
Mkt cap ! $2.523B | |||
| Open | High | Low | Value | Volume |
| $19.96 | $19.96 | $19.69 | $3.371M | 170.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 415 | $19.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.87 | 400 | 8 |
View Market Depth
| Last trade - 15.48pm 05/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |